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With improved understanding of the biology of differentiated thyroid carcinoma its management is
evolving. The approach to surgery for the primary tumour and elective nodal surgery is moving from a
“one-size-fits-all” recommendation to a more personalised approach based on risk group stratification.
With this selective approach to initial surgery, the indications for adjuvant radioactive iodine (RAI)
therapy are also changing. This selective approach to adjuvant therapy requires understanding by the
entire treatment team of the rationale for RAI, the potential for benefit, the limitations of the evidence,
and the potential for side-effects.
This review considers the evidence base for the benefits of using RAI in the primary and recurrent
setting as well as the side-effects and risks from RAI treatment. By considering the pros and cons of
adjuvant therapy we present an oncologic surgical perspective on selection of treatment for patients,
both following pre-operative diagnostic biopsy and in the setting of a post-operative diagnosis of
malignancy.
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Follicular cell-derived thyroid carcinoma (FCTC), when it is well
differentiated, is generally an indolent disease which can be
managed by surgery alone in most patients; papillary thyroid car-
cinoma (PTC) represents 80e85% of cases of FCTC and follicular
thyroid carcinoma (FTC) typically 10e15% [1]. Poorly differentiated
and undifferentiated (anaplastic) thyroid cancer will not be dis-
cussed in this review. The need for additional postoperative therapy
increases with the aggressiveness of disease. Radioactive iodine
(RAI) has long been known to have a role in the management of
both PTC and FTC and the goals of RAI therapy have recently been
defined as ablation of normal thyroid tissue (remnant ablation),
adjuvant treatment, or treatment of known disease (gross residual,
locoregional or distant spread) [2].
Options for disease management teams to consider when
managing PTC or FTC range from active surveillance, through
conservative surgical resection or aggressive initial surgery with
adjuvant RAI to the extreme end of the spectrum, i.e. therapeutic
RAI, external beam radiation and targeted therapies for the most
advanced cases [1]. For the majority of cases, who present with
localized disease confined to the neck, controversy surrounds
deciding whether the patient is a candidate for adjuvant RAI. As a
bilobar resection approach (whether near-total or total thyroidec-
tomy) is necessary to optimise RAI uptake, the decision to perform
more extensive surgery is critical for the surgeon, and guides pri-
mary surgical management, with potentially significant conse-
quences for the patient. International guidelines now outline an
approach to selection of patients for RAI based on potential for
oncological benefit [1e3]. However, a decision regarding the extent
of surgical intervention relies not only on such treatment-related
indications, but also complex aspects of the patient and their
tumour which affect decision making throughout. The aim of this
review is to consider the optimal approach to surgical management
andwill initially consider the evidence base supporting or opposing
the use of adjuvant RAI.
Initial experience with radioactive iodine
RAI was first employed in the management of thyroid cancer in
the 1940s when it was demonstrated that metastatic thyroid cancer
concentrated iodine and in 1942 Keston et al. reported RAI use in
treatment of a femoral metastasis [4]. For the next 25 years, reports
of the use of RAI in the treatment of thyroid cancer were published
in small series [5,6]. In 1967 Pochin [6] described RAI use in 200
patients with FCTC, “mainly with histologically differentiated and
inoperable tumours” which they treated over 18 years in London.
He demonstrated that RAI uptake developed in over 80% of differ-
entiated tumours after thyroid hormone withdrawal and reported
that an average of 6 RAI doses of 5550 MBq each was required over
3 years to abolish all evidence of remaining tumour activity. Clearly
all of these patients treated by Pochin would now be considered
high-risk using contemporary risk stratification methods.
By the 1970s comparative series were being published. Varma
et al. compared 263 patients treated in the era of I-131 to those
treated prior, and found that in patients 40 years and older, death
rates were significantly lower in patients treated with RAI than in
those who did not receive RAI. This difference was not observed for
younger patients [7]. Krisnamurthy and Blahd demonstrated that in
54 patients who achieved successful ablation, a lower death rate
was observed with a mean delivered dose of 9065MBq [8].
In the same year, Mazzaferri el al. [9} reported outcomes for 576
PTC patients treated at US Air Force Hospitals. His series of papers
not only described superior outcomes for PTC and FTC patients
treated with total thyroidectomy, in contrast to less than totalPlease cite this article as: Nixon IJ et al., The role of radioactive iodine in
oncologic surgical perspective, European Journal of Surgical Oncology, htthyroidectomy, but also demonstrated lower postoperative recur-
rence rates for those patients treated with RAI [9e11]. [9e11]. In a
subsequent re-analysis of the data, no improvement in recurrence
rates after RAI were seen in low-risk PTC patients with tumours
<1.5 cm in diameter [11]. Although these papers had a wide
reaching impact on the management of PTC, careful scrutiny of the
original (1977) report showed that the actual number of patients
treated with RAI following successful macroscopic excision of all
disease was limited (n ¼ 33), with the majority of patients having
unresected nodal disease or distant metastases [12]. Despite its
limitations, this 1977 paper influenced clinicians globally and
promoted the use of RAI following surgery for the majority of pa-
tients with either PTC or FTC. The interplay between RAI and
completeness of initial surgery was further demonstrated by the
Michigan group in 1984who found that successful RAI ablationwas
more difficult to achieve if a significant thyroid remnant was left
behind. They recommended performing the “best possible total
thyroidectomy” to aid successful remnant ablation [13].
However, not all endocrine oncologic groups agreed with the
findings reported by Mazzaferri el al. The MD Anderson group re-
ported outcomes for 706 patients with differentiated thyroid can-
cer (DTC) treated from the 1950s onwards. Although patients who
received RAI had fewer recurrences, this did not translate into
significant differences in either disease-free interval or survival
benefit [14]. In 1983 Snyder et al. [15] from theMayo Clinic reported
outcomes for 69 patients with PTC or FTC who had radioiodine
remnant ablation (RRA) after being initially treated with total or
near total thyroidectomy. Their finding that successful RRA did not
protect against locoregional recurrence, which occurred in 9% of
their DTC patients, led them to conclude that RRA in low-risk DTC
may represent a “questionable pursuit of an ill-defined goal” [15].
Risk stratification and adjuvant radioactive iodine
By the 1980s, the influence of prognostic factors on outcomes
and the concept of risk stratification in DTC had been well estab-
lished [16e19]. The Mayo Clinic group continued their detailed
analyses of the impact of therapy on outcome, time and again
demonstrating that, in low-risk PTC patients with MACIS scores
[19] of <6, there was no evidence that RRA improved recurrence
rates or survival after initial bilateral lobar resection with complete
resection of all grossly visible disease [20e23]. In 2012, Schvartz
et al. studied almost 1300 low-risk DTC patients managed over a 30
year period and found no impact on survival or disease free interval
associated with RAI [24]. The lack of impact demonstrated by RAI
use in low-risk cases has been supported by a number of recent
systematic reviews on the subject [25e27]. However, it should be
noted that much of the evidence in this field is retrospective and
subject to bias. As such, not all experts agree, as highlighted in a
recent joint statement from American and European Societies [28].
However, at the other end of the spectrum, for high-risk disease
oncological improvements were demonstrated both retrospec-
tively and in prospective cohort studies. In 1998, Taylor et al. in a
prospective North American multicentre study reported improved
recurrence and survival rates in high-risk PTC and FTC patients after
RAI therapy was administered following initial total or near-total
thyroidectomy [29]. Interestingly however, for PTC patients, when
tall cell variants were excluded the significance was lost [29].
Similar results were demonstrated by Jonklaas et al. in a later
analysis of the same National Thyroid Cancer Treatment Coopera-
tive Study (NTCTCS) Registry cohort where improved outcomes
were reported from stage II-IV patients following RAI, which were
not seen for stage I patients [29,30]. In aggressive variants of DTC,
such as insular and Hurthle cell carcinoma, National Cancer Data
Base (NCDB) analysis has also suggested a role for RAI in reducingthe management of patients with differentiated thyroid cancer e An
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to show a survival benefit in older patients with larger tumours,
nodal metastases and M1 disease [34].
Therefore, for high-risk and low-risk patient groups, the posi-
tions are clear both for and against the routine use of RAI, respec-
tively. However, a large group of patients present with disease
considered to represent an intermediate risk. This group has proven
difficult to study for a number of reasons. Firstly, outcomes are
favourable with few deaths and a limited number of recurrences.
Secondly, classification of intermediate-risk disease is variable be-
tween studies. The American Thyroid Association (ATA) classifies
intermediate-risk disease as demonstrating microscopic extra
thyroidal extension (ETE), significant nodal disease or adverse
histological features [1]. However, recent data have suggested
microscopic ETE and extension in to the strap muscles (the most
common site) to be lower risk than previously considered [35e37],
factors which had not been considered in historical studies.
Analysis of the Surveillance, Epidemiology, and End Results
Program (SEER) database has shown that with huge cohorts of
patients, statistically significant differences in survival for
intermediate-risk patients can be demonstrated. However, with
survival differences of as little as 1% in some groups and the
methodological limitations of such datasets, the clinical signifi-
cance of these findings has been questioned [38]. Chow et al.
retrospectively demonstrated a recurrence advantage when inter-
mediate risk patients were managed with RAI, with the greatest
advantage reported in those with the most advanced nodal disease
[39]. Similar findings have been shown prospectively by Jonklaas
et al. [29] reporting on behalf of the NTCTCS Group. The results of
this analysis are complex, however, as some patients who would
now be considered as intermediate risk of recurrence (younger
patients with N1 disease) were categorised as low-risk in this study,
and no benefit was demonstrated in this stage I disease. In keeping
with these findings, the Mayo Clinic also reported no benefit in
patients with nodal disease who were categorised as low risk [40].
These inconsistent findings are recognised in systematic reviews of
the subject reporting a similar number of studies which demon-
strate the benefit of RAI in intermediate risk disease to those that do
not [27]. It is hoped that over the coming years, the “Iodine or Not”
trial from the United Kingdom, which is randomising intermediate
risk patients to RAI or not following total thyroidectomy, will help
clarify the position in this challenging group of patients [41].
It is important however to understand that simply the discovery
of a well differentiated FCDC in a lobectomy specimen is not of
necessity an indication for completion thyroidectomy. Most pa-
tients with unifocal, intrathyroidal (low-risk) tumours may be
cured with unilateral lobectomy alone. The need for completion
total thyroidectomy should be carefully studied, as few patients
with such minimal disease will benefit from adjuvant RAI, and
therefore do not require a completion thyroidectomy.
The use of RAI as an alternative to completion thyroidectomy
has been reported in small case series. The concept is particularly
attractive in those patients who have had a diagnostic lobectomy
and are found to have high-risk malignancy on final pathology, or
have positive margins or gross extra-thyroidal extension of disease
which may make it unresectable [42]. Due to potential risks of
completion surgery, some groups have used RAI “lobectomy” in this
setting. This may be considered suitable for patients who are at
extremely high risk from further surgery, following initial recurrent
laryngeal nerve injury [43e46]. However, experience is limited and
this is not a widely accepted practice at present. There are potential
drawbacks to this approach, as the residual normal thyroid tissue
will absorb much of the activity, limiting the activity absorbed by
residual thyroid cancer cells.
Therefore, at present, the results of progress in addressing thePlease cite this article as: Nixon IJ et al., The role of radioactive iodine in
oncologic surgical perspective, European Journal of Surgical Oncology, htquestion of whether RAI should be used in the management of DTC
have been clarified for the most advanced cases, where its use is
widely supported [47]. To some degree in the lowest-risk cases
clinicians agree that there is no impact on outcome. For a large
group of intermediate-risk cases however, the evidence remains
conflicted (Tables 1 and 2). Given the low rates of recurrence in this
group (5e20% [1]) and the large cohort size therefore required,
coupled with the prolonged follow-up necessary, it is unlikely that
any oncological advantage of adjuvant RAI will ever be proven for
intermediate-risk patients.
What dose of adjuvant radioactive iodine?
In addition to the debate over the need for RAI, there has also
been controversy over the doses required for treatment. In 1987,
Creutzig et al. reported similar rates of successful ablation using
low (1100MBq) versus high dose (3700MBq) treatment [48].
Similar results were reported in a prospective randomised trial of
63 patients assigned low versus high dose treatment without any
demonstrable difference in post ablation outcomes on the 6 week
post-treatment scan [49]. Bal et al. also found no improved efficacy
with higher doses of RAI, recommending nomore than 1850MBq as
the target dose following total thyroidectomy [50]. The same group
went on, in larger prospective trials to recommend a dose between
925 and 1850MBq [51] and ultimately to conclude in 2012 that
similar outcomes were seenwith low, intermediate or high doses of
RAI and that they were probably administering too much iodine in
remnant ablation [52]. Rosario et al. found similar results in 2004
[53], as have many subsequent groups over the past 2 decades
[54e60].
In contrast, Gawkowska-Suwinska et al. found a marginal
improvement in post ablation results in 220 patients with T1b-T3
N0M0 DTC treated with a higher dose of RAI, when comparing
2220MBq versus 1110MBq) [61]. Zaman et al. also found higher
rates of successful ablation (60% versus 40%) for 40 patients treated
with 3700MBq versus 1850mBq [62]. In 2012, Fallahi et al. rec-
ommended high dose (3700MBq) RAI for remnant ablation
following a randomised trial of 341 patients in whom the low dose
group (1110MBq) had higher rates of requiring a second dose of I-
131 (64% versus 39% successful ablation for high versus low dose
respectively), resulting in higher overall activity levels being
delivered and more in-patient time [63].
In 2012, the New England Journal of Medicine published two
landmark trials of low- versus high-dose RAI in low-risk DTC
[64,65]. Mallick et al. reported similar levels of post ablation success
and a lower rate of adverse events for 438 patients with T1-T3
tumours treated with 1110MBq versus 3700MBq in a multicentre
randomised trial in the United Kingdom [64]. Schlumberger et al.
included over 700 patients with T1-2,N0-1 DTC treated at 24 French
centres with 1110MBq versus 3700MBq. Again, outcomes in both
groups were comparable with excellent post-ablation outcomes
(92% complete ablation) with the authors concluding that the lower
dose may be sufficient for ablation of remnant thyroid tissue. In an
accompanying editorial Alexander and Larsen [66] noted that both
RAI doses were equally effective at reducing serum Tg to a very low
level and eliminating residual thyroid tissue, as seen on ultraso-
nography, and that thyroid ablation occurred even in patients with
pathologically confirmed regional node involvement. They felt the
results from both studies should change standard practice, but also
did raise the question of whether any RAI is required for low-risk
patients “since 21e59% of patients in these two studies had
already met the goal of a low Tg level after thyroidectomy alone”
[66].
Radioiodine remnant ablation is the term used for postoperative
treatment without clear evidence of ongoing malignancy which isthe management of patients with differentiated thyroid cancer e An
tps://doi.org/10.1016/j.ejso.2020.01.010
Table 1
Low, intermediate and high-risk stratification (adapted from the American Thyroid Association Guidelines [2]).
Papillary Carcinoma Follicular Carcinoma
Low Risk  T1-2,N0,M0
 Complete resection
 No aggressive histology
 No vascular invasion
 Clinically N0 or <5 nodes all with less than 2 mm deposits
 Multifocal microcarcinoma
 <4 foci vascular invasion
Intermediate Risk  Microscopic extra thyroidal extension
 Aggressive histology
 Vascular invasion
 Clinically N1 (no nodes >3 cm)
 RAI-avid metastatic nodes in neck on post treatment scan
 Microscopic extra thyroidal extension
 Clinically N1 (no nodes >3 cm)
 RAI-avid metastatic nodes in neck on post treatment scan
High Risk  Gross extra thyroidal extension
 Incomplete resection
 M1 (structural of thyroglobulin suggestive)
 N1 disease and node >3 cm
 Follicular carcinoma with >4 foci of vascular invasion
Table 2
Factors related to decision to offer completion thyroidectomy for RAI following initial lobectomy.
Favour Completion for RAI Favour Observation
Age Older Younger
Personality Anxiety about recurrence Anxiety about side effects of treatment
Occupation Professional voice user
Ultrasound Contralateral nodular disease Normal contralateral lobe
Histology Significant lymphovascular invasion, multifocality, low volume nodal
disease, extra-thyroidal extension
Small volume primary, pN0 disease
Functional status No swallowing difficulty, no contraindication to general anaesthesia Swallowing difficulty, contraindications to general anaesthesia,
challenging initial surgery
I.J. Nixon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx4designed to eliminate thyroid bed gland remnants which may
persist after total thyroidectomy and may also serve to stage other
disease sites not recognised at first surgery [28]. Thyroid bed up-
take is nearly universal after even expert total thyroidectomy and a
classification system has been generated to describe its pattern
[67].
These results suggest therefore that there is likely little benefit
in increasing doses of RAI in patients treated for low or
intermediate-risk disease. Whether low dose is as good as no dose
is a question that remains to be answered [41]. At present one new
multicentric trial (IoN) in the United Kingdom is being carried out
to address this question [41].
Radioactive iodine for recurrent differentiated thyroid cancer
As stated above, evidence supporting the use of RAI in the pri-
mary setting is of low quality and conflicted for many patient
groups. Unfortunately, there is even less evidence in the setting of
recurrent disease [68].When locoregional recurrence is structurally
identified, surgery is first in the hierarchy for treatment [1].
Following surgery, in the absence of distant metastases, there is
little evidence to support RAI.
Hung et al. reported no difference in outcome for 102 patients
treated for recurrent PTC with or without RAI in long-term follow-
up [69]. Similar findings were reported by Yim et al. who limited
their analysis to PTC patients with a detectable stimulated Tg level
following re-operative surgery [70].
In patients who have a rising serum thyroglobulin (Tg) level but
an absence of structurally evident recurrent disease the role of
“empiric” RAI is unclear. It can be used to identify sites of disease or
in an attempt to reduce Tg levels. However, such an approach has
not been shown to result in improved survival. Consequently, the
ATA guidelines [2] do not recommend such an approach, but
recommend consideration of RAI in this setting only when the TgPlease cite this article as: Nixon IJ et al., The role of radioactive iodine in
oncologic surgical perspective, European Journal of Surgical Oncology, htlevels are rapidly rising. They highlight the fact that this is a weak
recommendation based on low-quality evidence [1].
In the absence of strong data on which to base decisions, again
treatment teams must consider a number of variables. In low-risk
patients who manifest disease in the contralateral lobe following
initial thyroid lobectomy, simple completion thyroidectomymay be
sufficient. For those patients who develop high volume regional
recurrence, surgical excision can be followed with assessment of
serum Tg on throxine suppressive therapy.
Side effects of radioactive iodine
Although RAI has significantly less morbidity than external
beam radiotherapy, it is not without side effects. These are dose
related and expressed by the additional tissues which concentrate
iodine, namely salivary and lacrimal glands [71e73].
Some patients complain of acute taste disturbance, and chronic
dry eyes and a dry mouth, which contributes to difficulty in swal-
lowing [72,74]. RAI treatment is associated with increased rates of
sialadenitis [75] which in turn can have a significant impact on
quality of life [76,77]. Indeed there is a reported 20% rate of
dysfunctional salivary glands five years following RRA [78].
Symptoms of obstructive sialadenitis following RAI can currently be
helped by sialendoscopic dilatation, rinsing and corticosteroid in-
jection, a therapeutic option that many thyroid oncologists are
unaware of [79].
In addition, there is a reported slightly increased risk of sec-
ondary haematological and salivary malignancy in patients who
have received increasing doses of RAI, although this is unlikely to
impact decisions at an individual level [80e82].
Therefore, the side-effects of RAI are both acute and long term.
Although relatively mild in comparison with those related to
external beam radiation, the chronic effects remain problematic in
a group of patients who can expect long-term survival.the management of patients with differentiated thyroid cancer e An
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Despite conflicting evidence, guidelines on the management of
DTC have attempted to provide a consensus approach. In 2009 the
ATA guidelines recognised the conflicting data but recommended
RAI for all high-risk patients and selected patients with 1e4 cm
tumours and any high-risk feature. RAI was routinely recom-
mended for high-risk patients with macroscopic ETE or significant
regional or distant metastases. Microcarcinomas (<1 cm) were
recommended not to receive RAI [83]. A similar approach was
adopted in the UK with a recommendation to consider RAI in all
cases other than classical micropapillary carcinoma in the British
Thyroid Association (BTA) Guidelines [2]. In the 2015 updated ATA
guidelines, a slight move away from an almost universal recom-
mendation for RAI has been seen. The ATA guidelines now do not
recommend RAI in low risk cases but consider its use in interme-
diate risk cases, particularly as risk factors such as advanced age
and nodal burden increase [1]. However, mainland European
groups have not endorsed such a move, pointing to the lack of
prospective evidence to support it [28,84,85].
Given the conflicting evidence, combined with general support
for RAI in most cases provided by powerful international guideline
statements, it is hardly surprising that rates of RAI have been rising.
Whereas in the 1990s around 40% of patients with tumours over
1 cm received RAI in the USA this had risen to over 60% by 2008
[86]. However, there is some suggestion that rates may now be
starting to fall for lower-risk patients in the USA [87]. Within these
findings there was significant heterogeneity of approach based on
both patient and clinician factors suggesting continued uncertainty
for many involved in this field.
Although exact causes for this variation in practice are unclear,
they are likely to be influenced by multiple factors. The environ-
ment of clinical practice has been shown to be critical with high-
volume centres more commonly recommending RAI [86]. Howev-
er, approaches to imaging and pathological processing of surgical
specimens have also evolved over the decades. There is an ever-
increasing level of scrutiny applied to each case in order to iden-
tify evidence of higher risk features such as previously occult nodal
disease on ultrasound scan, and adverse histological features on
pathology. The increase in frequency of prophylactic central neck
dissection has produced a stagemigration, that also induces the use
of more RAI. Such an approach leads to an increasing number of
patients identified as having higher-risk features which further,
encourage treatment intensification [88].
Radioactive iodine and the surgeon
When considering the initial approach to DTC, the surgeonmust
consider a number of factors. Initial investigations may clearly
identify patients who should or should not receive RAI and must
therefore be dealt with appropriately. Examples would include a
proven intra-thyroidal carcinoma without regional or distant dis-
ease. Such patients do not benefit from RAI and do not require total
thyroidectomy to facilitate adjuvant therapy. In contrast, patients
with significant nodal disease, distant disease or gross posterior
macroscopic extra-thyroidal extension will require RAI and should
undergo total thyroidectomy [1,2,89].
For the majority of patients, however, the situation is less clear
and an individualised approach is recommended by guidelines. It is
now well recognised that for patients with intrathyroidal disease,
in the absence of high-volume nodal disease, distant disease or
posterior gross extra-thyroidal extension [37], outcomes are
excellent irrespective of whether or not adjuvant RAI is used.
Selecting patients for RAI based on pre-operative staging may
therefore not be possible. A 2 cm cytologically proven PTC withoutPlease cite this article as: Nixon IJ et al., The role of radioactive iodine in
oncologic surgical perspective, European Journal of Surgical Oncology, htevidence of regional disease may, on surgical pathology prove to
have significant lymphovascular invasion or adverse histological
features whichwould prompt consideration of RAI. In contrast, for a
classic papillary thyroid carcinoma without such features, treat-
ment with lobectomy alone may be sufficient.
For many patients then, the surgeon needs to consider a variety
of non-cancer factors prior to intervention. For example, is there a
background ofmultinodular disease? If there is, particularly if these
are not all ultrasonically benign in appearance, consideration
should be given to total thyroidectomy versus lobectomy. Is there a
reason to consider the patient particularly vulnerable to recurrent
laryngeal nerve injury? Professional voice users, patients with pre-
existing nerve palsies or those with an unsafe swallow prior to
intervention may be more suitable for lobectomy rather than total
thyroidectomy. For clinicians practicing in areas of the world where
ready supplies of supplements such as calcium and vitamin D are
not easily obtainable, a more conservative approach may be fav-
oured to avoid long-term complications associated with a lack of
supplementation [90]. Based on these clinical factors, in addition to
the initial pre-operative clinical tumour staging, the surgeon will
then provide a surgical specimen of either total thyroidectomy or
lobectomy. Analysis of the tumour within will then dictate further
management. Of course, discussion as to the extent of thyroidec-
tomy with a clinical endocrinologist would be important as he/she
will likely contribute significantly as part of a multi-disciplinary
team in the overall case management, particularly in long-term
postoperative follow-up.
When a total thyroidectomy has been performed, the patient is
in a position to receive an ablative dose of RAI if indicated. This is
particularly important if the operation was a sub-total thyroidec-
tomy, where RAI was historically used for thyroid remnant ablation
to facilitate follow up. It is therefore crucial that, when a total
thyroidectomy is contemplated, it should be a “true extra capsular
total thyroidectomy”, leaving no thyroid tissue behind, thus
avoiding the need for “remnant ablation”. Such an approach often
renders the Tg level undetectable without the need for RAI to ablate
residual normal tissue in the hope of achieving an undetectable Tg.
Consideration of pathological details including tumour size,
adverse histology, associated nodal metastases and clinical findings
in the operating room will all contribute to the multidisciplinary
decision regarding the need for RAI therapy, not just remnant
ablation. Many patients with thyroid cancer have significant anxi-
ety regarding the disease [91e93], despite the excellent outcomes
and the threshold for administering adjuvant RAI is correspond-
ingly low.
If thyroid lobectomy has been performed, a similar process of
consideration of the pathology should be performed. At present,
international guidelines make recommendations regarding in-
dications for RAI based on oncological factors alone. The current
ATA guideline for example recommends completion thyroidectomy
when a total thyroidectomy would have been recommended if the
diagnosis had been available prior to initial therapy [1]. However,
this is an oversimplification of the situation at the point of
considering further surgery.
In contrast to the patient who underwent total thyroidectomy,
adjuvant RAI will require a readmission for completion thyroidec-
tomy. It has been well demonstrated that this procedure rarely, if
ever, results in additional primary disease risk factors being iden-
tified other than previously occult small volume multifocal disease
[94,95]. Therefore, clinicians should recognise that this procedure is
only performed to facilitate RAI. The risks of completion thyroid-
ectomy are not insignificant with long-term complications recor-
ded in up to 10% of cases [96,97]. Such an approach should only be
recommended if the management team consider the benefit of RAI
to exceed the inconvenience and risk of further admission forthe management of patients with differentiated thyroid cancer e An
tps://doi.org/10.1016/j.ejso.2020.01.010
Fig. 1. Flow chart for surgical planning in differentiated thyroid cancer.
I.J. Nixon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx6surgery and then radiation and the associated long-term side ef-
fects. In practice this can be a difficult estimate to make. For lesions
which demonstrate widely accepted high risk features such as tall
cell variant PTC or gross extra-thyroidal extension, RAI will be
indicated. For low-risk lesions without any adverse features, no
further therapy is required. A framework for considering the situ-
ation following treatmentwithout RAI based on imaging and serumPlease cite this article as: Nixon IJ et al., The role of radioactive iodine in
oncologic surgical perspective, European Journal of Surgical Oncology, htTg levels in the post-surgical setting has been reported byMomesso
et al. [98].
Many patients, however will have disease which is difficult to
risk stratify. The presence of multifocality for example, uncertainty
regarding lymphovascular invasion, small volume incidentally
excised metastatic nodes or the presence of microscopic extra
thyroidal extension are all risk factors which were not part of thethe management of patients with differentiated thyroid cancer e An
tps://doi.org/10.1016/j.ejso.2020.01.010
I.J. Nixon et al. / European Journal of Surgical Oncology xxx (xxxx) xxx 7original risk stratification systems but are now routinely reported.
For these cases the surgeonmust recognise not only the oncological
uncertainty regarding the importance of these factors but also
more subtle features of the patient. These will include age, the
patient's personality, occupation and pre- and post-operative
functional status. In addition, findings in the operating room may
influence the recommendation for further surgery. In lower risk
cases where surgical anatomy or physiological fitness made a case
challenging, the risk of surgery is higher and may outweigh the
potential benefit of adjuvant RAI (Table 2).
Brief mention of the regional lymphatics should also be made.
Although the role of therapeutic neck dissection is generally
accepted, that of elective surgery remains highly controversial. In
the setting of selection of patients for RAI, some groups recommend
elective staging of the neck in order to more accurately identify
those patients who may benefit from RAI [88]. This practice iden-
tifies occult central neck disease in around one third of patients.
These patients are then considered for RAI treatment based on
nodal factors rather than primary disease features alone. However,
such an approach has never been shown to be beneficial in terms of
recurrence or survival and many groups who choose to leave such
cN0 necks undissected do so without any evidence of adverse
outcome for their patient groups [99]. Clinicians who choose this
approach to treatment should understand that, although they may
demonstrate pN0 disease in many patients and thereby reduce
pressure to consider adjuvant RAI, they will also upstage a signifi-
cant number of patients with small volume nodal disease for whom
most teams will feel compelled to recommend further therapy
without clear evidence of benefit.
The surgeon factor must also be considered. The relationship
between surgical volume and complications is clear [100], but the
relationship with complete thyroidectomy is poorly explored. The
definition of total thyroidectomy is heterogenous, and some sur-
geons leave a small piece of thyroid gland near Berry's ligament or
the upper poles in order to protect the recurrent laryngeal nerve or
the parathyroid glands. Surgeons who perform this type of surgery
will experience a higher post-operative serum Tg level in their
patients. In some practices, it is assumed that RAI will compensate
for this surgical approach; however, it may partially explain dif-
ferences between rates of use of RAI.
Finally, the patient's wishes must be considered. Some patients
press to receive RAI under the assumption that it will offer an
advantage. In many practices, this pressure is hard to manage and
some treatment teams may feel obliged to offer RAI evenwhen not
fully convinced of its oncological benefit.
Conclusion
In common with many aspects of the management of patients
with DTC, the role of adjuvant RAI is complex and hindered by a
significant amount of low-quality evidence. Early evidence
demonstrated the potential that RAI had in treating the most
advanced thyroid cancers. In the middle of the 20th century RAI
became the standard of care for the majority of cases. However, the
advent of risk stratification allowed identification of low-risk
groups with little to gain from adjuvant therapy and high-risk
groups who gained the most. Most recently, high-quality pro-
spective clinical trials are demonstrating a reducing role for
radioactive iodine, limiting its use to higher-risk cases. This
decrease in use of routine RAI also withdraws one of the former
reasons for total thyroidectomy (to facilitate RAI) and dovetails
with our increasing awareness of lobectomy as an adequate initial
treatment for patients with smaller tumours without extra-
thyroidal extension or clinically apparent nodal disease. It is critical
therefore that the modern thyroid surgeon appreciates patient,Please cite this article as: Nixon IJ et al., The role of radioactive iodine in
oncologic surgical perspective, European Journal of Surgical Oncology, httumour and background thyroid-related factors which will influ-
ence decisions regarding initial surgical therapy (Fig.1). By carefully
balancing the information available at the pre-surgical, peri-oper-
ative and post-operative stages, the surgeon can provide person-
alised recommendations which aim to optimise both oncological
and functional outcomes for patients with DTC.
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